Treatment of Acne Vulgaris With Doryx Tablets Compared to Doxycyline Hyclate
NCT ID: NCT00635609
Last Updated: 2012-04-20
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
93 participants
INTERVENTIONAL
2008-03-31
2008-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Treatment of Moderate to Severe Facial Acne Vulgaris
NCT00612573
A Novel Combination Oral Agent to Treat Acne Vulgaris
NCT01301586
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
NCT00666900
Subantimicrobial Doxycycline in Acne
NCT05399290
Explorative Trial Evaluating the Efficacy and Tolerability of LEO43204 in Moderate to Severe Acne
NCT02575950
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Doxycycline hyclate (Doryx)
Doxycycline hyclate (Doryx)
150mg/day, oral, delayed release tablets
Doxycycline hyclate
Doxycycline hyclate
100 mg/day, oral, tablets, immediate release
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxycycline hyclate (Doryx)
150mg/day, oral, delayed release tablets
Doxycycline hyclate
100 mg/day, oral, tablets, immediate release
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Has a diagnosis of facial acne vulgaris with no more than two nodules on the face.
Exclusion Criteria
* Has a history of pseudomembranous colitis or antibiotic-associated colitis.
* Has a history of hepatitis or liver damage or renal impairment.
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Warner Chilcott
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Angelo Secci, MD
Role: STUDY_DIRECTOR
Warner Chilcott
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Warner Chilcott Investigational Site
Vista, California, United States
Warner Chilcott Investigational Site
Miami, Florida, United States
Warner Chilcott Investigational Site
Louisville, Kentucky, United States
Warner Chilcott Investigational Site
Rochester, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PR-08607
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.